Alerts8.23.24
HHS-OIG Highlights Fraud, Abuse Concerns With Manufacturer Offering Financial Assistance to Treat Infertility Side Effects
The HHS-OIG issued an unfavorable opinion on whether a pharma manufacturer may offer financial assistance to patients if they have significant side effect from its gene therapy product
The Office of Inspector General of the U.S. Department of Health and Human Services (HHS-OIG) has issued Advisory Opinion No. 24-06, an unfavorable opinion regarding proposed financial assistance from the manufacturer of a gene therapy product for certain qualifying patients who may need fertility services after receiving such gene therapy treatment.
Keep Up to Date in a Changing World
Do you want to receive more valuable insights directly in your inbox? Visit our subscription center and let us know what you’re interested in learning more about.
